BCIRT-01NCT05975307
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
StatusActive, Not Recruiting
PhasePhase 2
SponsorSun Yat-sen University
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Secondary endpoints: 7 to 6
- Notable Primary completion pushed from Dec 31, 2025 to Dec 31, 2026
- Eligibility criteria shortened, about 2 words
Notable Primary completion date: Dec 31, 2025 to Dec 31, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 17 words
- Enrollment target: 71 to 64
- Secondary endpoints: details revised at 1 of 7 entries
- Study description revised
- Minor Enrollment target: 64 to 71
- Primary completion date: Aug 31, 2025 to Dec 31, 2025
- Secondary endpoints revised (7)
- Minor Secondary endpoints: 8 to 7v6
Show 4 earlier versionsHide 4 earlier versions
- Notable Primary completion date: Dec 31, 2024 to Aug 31, 2025
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Minor Start date changed from estimate of Nov 21, 2023 to Dec 1, 2023v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Aug 1, 2023 to Nov 21, 2023
- Site details revised
- Minor Secondary endpoints: details revised at 1 of 8 entries
- Study description expanded, about 5 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Clinical complete response (cCR) rate
Timeframe: When the eligible patients complete the treatment and followed-up for half a year
Secondary (6)
Overall survival (OS)
Bladder-intact event-free survival (BI-EFS)
Disease-free survival (DFS)
Local recurrence (LR) rate
Incidence of grade 3/4 (G3/4) toxicities
Show 1 moreShow less
Bladder function
Arms and interventions
Toripalimab plus chemoradiationExperimental
This study has only single arm in which the patients will receive neoadjuvant chemotherapy plus anti-PD-1 therapy (toripalimab), followed by radiotherapy plus concurrent anti-PD-1 therapy
Drugs: Toripalimab, Gemcitabine, Cisplatin, Carboplatin
Radiation: Intensity-modulated radiation therapy
Sites
1 site in 1 country
- Cancer Center, Sun Yat-sen UniversityGuangzhou, Guangdong, China